Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

2 evidence topics · 2 sources

Vial content

“Each vial contains 11 mg imlifidase produced in Escherichia coli cells by recombinant DNA technology.” (opens the source at this quote in a new tab)

Pharmaceutical form

“Powder for concentrate for solution for infusion” (opens the source at this quote in a new tab)

Material safety data sheet for the medicinal product

No evidence found.